Svastijaya Daviratanasilpa, MD
Nephrology · Dover, DENPI 1720291404
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,298, 3.8 times the $340 reported in 2019.
Across 174 payments — averaging $26.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$757
- AstraZeneca$422
- Mallinckrodt Hospital Products Inc.$317
- Otsuka America Pharmaceutical, Inc.$295
- Boehringer Ingelheim$279
- Akebia Therapeutics Inc$260
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,54197%
- Education$1223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 18 | $757 |
| AstraZeneca(2 entities) | 14 | $422 |
| Mallinckrodt Hospital Products Inc. | 10 | $317 |
| Otsuka America Pharmaceutical, Inc. | 11 | $295 |
| Boehringer Ingelheim | 8 | $279 |
| Akebia Therapeutics Inc | 13 | $260 |
| Fresenius USA Marketing, Inc. | 11 | $241 |
| Vifor Pharma, Inc. | 9 | $227 |
| Novartis | 8 | $186 |
| Bayer | 8 | $154 |
| Aurinia Pharma U.S., Inc. | 6 | $154 |
| Calliditas Therapeutics US Inc. | 7 | $149 |
| Ardelyx, Inc. | 8 | $143 |
| Novo Nordisk | 2 | $139 |
| GSK | 7 | $135 |
| Lilly USA, LLC | 3 | $81 |
| Sanofi | 3 | $76 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $74 |
| Shield Therapeutics Inc | 2 | $73 |
| Travere Therapeutics, Inc. | 6 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $65 |
| Mozarc Medical US LLC | 2 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Cycle Pharmaceuticals Inc | 1 | $28 |
| Amicus Therapeutics, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Argon Medical Devices, Inc. | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,663 in reported general payments places this provider in the 70th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 175 | $233,889 |
| FarxigaDapagliflozin Propanediol | 71 | $74,315 |
| KerendiaFinerenone | 37 | $50,995 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $35,227 |
| Cinacalcet Hcl | 12 | $32,525 |
| Potassium Citrate ErPotassium Citrate | 160 | $20,515 |
| EliquisApixaban | 14 | $17,502 |
| Sevelamer Carbonate | 48 | $14,351 |
| Allopurinol | 351 | $4,473 |
| Calcium Acetate | 26 | $3,013 |
| Potassium Chloride | 18 | $2,733 |
| Calcitriol | 93 | $2,318 |
| Losartan Potassium | 179 | $1,945 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 15 | $1,569 |
| Nifedipine ErNifedipine | 43 | $1,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $279 | $233,889175 claims |
| AstraZenecaFarxiga, Lokelma | $422 | $109,54397 claims |
| BayerKerendia | $154 | $50,99537 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $65 | $1,22711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 49 nephrology providers in Delaware.
Other nephrology in Dover
- Gerald MilanDover$16K
- Gertrude Findley-ChristianDover$8K
- Sumanth KacharamDover$7K
- Sangeetha SatyanDover$6K
- Manmeet BrarDover$2K
- Daniel CoarDover$721
- Lakshmi MenonDover$141
- Prayus TailorNewark$127K
- William DahmsNewark$94K
- Theodore SaadNewark$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.